daunorubicin has been researched along with Cancer, Second Primary in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (16.33) | 18.2507 |
| 2000's | 18 (36.73) | 29.6817 |
| 2010's | 12 (24.49) | 24.3611 |
| 2020's | 11 (22.45) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, KJ; Farrar, JE; Federico, SM; Hu, Y; Lei, S; Lewis, S; Nichols, KE; Onciu, M; Ribeiro, RC; Rubnitz, JE; Salek, M; Takemoto, CM; Triplett, BM; Wlodarski, MW; Zhang, J | 1 |
| Faderl, S; Goldberg, SL; Lancet, JE; Lin, TL; Newell, LF; Ryan, RJ; Uy, GL; Wieduwilt, MJ | 1 |
| Chan, O; Deutsch, Y; Eatrides, J; Jain, AG; Komrokji, R; Kuykendall, A; Lancet, J; Lee, D; Padron, E; Sallman, D; Sweet, K; Talati, C | 1 |
| Asubonteng, K; Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Prebet, T | 1 |
| Matthews, A; Pratz, KW | 1 |
| Ball, B; Baron, J; Famulare, C; Fazal, S; Goldberg, AD; Griffiths, EA; Przespolewski, A; Sanikommu, SR; Stahl, M; Sweet, K; Talati, C; Thompson, JE; Thota, S; Vachhani, P; Waksal, J; Wang, ES | 1 |
| Au-Yeung, R; Kwong, YL; Sim, JPY | 1 |
| Kasner, MT | 1 |
| Alati, C; Audisio, E; Bertani, G; Bilio, A; Caizzi, M; Candoni, A; Carnevale-Schianca, F; Cerrano, M; Cignetti, A; Clavio, M; D'Ardia, S; Dargenio, M; Ferrara, F; Fianchi, L; Fracchiolla, N; Galimberti, S; Gottardi, M; Grimaldi, F; Guolo, F; Gurreri, C; Lemoli, RM; Minetto, P; Morselli, M; Musto, P; Pagano, L; Pasciolla, C; Pavesi, F; Pietrantuono, G; Rizzuto, G; Rondoni, M; Rossi, G; Scappini, B; Scattolin, AM; Tafuri, A; Zappasodi, P | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| Plesa, A; Thomas, X | 1 |
| Cortes, JE; Faderl, S; Lancet, JE; Lin, TL; Ryan, RJ; Uy, GL | 1 |
| Banerjee, K; Bixby, DL; Chiarella, M; Cortes, JE; Hoering, A; Hogge, D; Kolitz, JE; Lancet, JE; Lin, TL; Louie, AC; Medeiros, BC; Newell, LF; Ritchie, EK; Ryan, DH; Schiller, GJ; Solomon, SR; Stone, RM; Strickland, SA; Stuart, RK; Uy, GL; Wieduwilt, MJ | 1 |
| Shea, LK; Uy, GL | 1 |
| Chuman, H; Furuta, K; Hiramoto, N; Hosoi, H; Kobayashi, Y; Maruyama, D; Nomoto, J; Takeda, K; Tobinai, K; Tochigi, N; Watanabe, T; Yagyu, S | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Ritter, J; Sander, A; Schrauder, A; Starý, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Chung, NG; Jang, W; Kim, M; Lee, JW | 1 |
| Su, Y; Zhang, L; Zhang, R; Zhou, X | 1 |
| Bendle, M; Bower, M; Papanastasopoulos, P; Pealing, J | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Betancourt-García, RD; Castro, J; Fernández, AC; Fradera, J; López-Enríquez, A; Pacheco, E | 1 |
| Cario, G; Coulthard, SA; Dördelmann, M; Eichelbaum, M; Kaatsch, P; Möricke, A; Reiter, A; Riehm, H; Schaeffeler, E; Schrappe, M; Schrauder, A; Schwab, M; Stanulla, M; Welte, K; Zimmermann, M | 1 |
| Baubion, N; Buzyn, A; Decaudin, D; Delarue, R; Fourquet, A; Ghez, D; Hermine, O; Messas, E; Rubio, MT; Suarez, F; Varet, B; Willems, L | 1 |
| Altman, J; Kuzel, T; Parajuli, R; Perdekamp, M; Tallman, M | 1 |
| Baila, L; Benoit, Y; Bertrand, Y; Boutard, P; Ferster, A; Lescoeur, B; Mazingue, F; Mechinaud, F; Millot, F; Munzer, M; Philippet, P; Plouvier, E; Renard, M; Robert, A; Suciu, S; Uyttebroeck, A; van der Werff Ten Bosch, J; Vandecruys, E | 1 |
| Bain, BJ; Innes, A; May, PC; Pavlů, J | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Bayraktaroglu, T; Borazan, A; Demircan, N; Ozdemir, H; Ozer, T; Savranlar, A; Ustündag, Y | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY; Lau, YL; Shek, TW | 1 |
| Alsop, S; Elenitoba-Johnson, KS; Lim, MS; Sanger, WG | 1 |
| Bartels, DB; Claviez, A; Dördelmann, M; Dynybil, C; Löning, L; Schrappe, M; Stanulla, M | 1 |
| Behm, FG; Boyett, JM; Hancock, ML; Krance, RA; Mahmoud, HH; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Sandlund, JT | 1 |
| Preisler, H | 1 |
| Ikeda, K; Kubota, Y; Murata, M; Nagai, M; Ohnishi, H; Sasaki, K; Takahara, J; Tanaka, T; Taoka, T; Tasaka, T | 1 |
| Ikeda, K; Inoo, M; Murao, S; Murata, M; Nagai, M; Sasaki, K; Takahara, J; Tasaka, T; Tokuda, M | 1 |
| Cleary, ML; Davis, RE; Kamel, OW; Soslow, RA; Warnke, RA | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Appelbaum, FR; Chen, IM; Godwin, J; Head, DR; Kopecky, KJ; Leith, CP; McConnell, T; Slovak, ML; Willman, CL | 1 |
| Baccarani, M; Candoni, A; Damiani, D; Ermacora, A; Geromin, A; Grimaz, S; Masolini, P; Michelutti, A; Michieli, M; Raspadori, D; Scheper, RJ; Stocchi, R | 1 |
| Hayakawa, A; Kosaka, Y; Nakamura, H; Piao, JH; Sano, K | 1 |
| Eden, OB; Gibson, B; Hann, I; Hill, F; Kinsey, S; Lilleyman, J; Mitchell, C; Richards, S; Vora, A | 1 |
| Akiyoshi, K; Eguchi, H; Hara, T; Inada, H; Ishii, E; Koga, H; Matsuzaki, A; Miyazaki, S; Nagatoshi, Y; Nakayama, H; Nibu, K; Okamura, J; Take, H; Tamai, Y; Yanai, F | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Andreeff, M; Brenner, MK; Goodell, MA; Kuehnle, I; Marini, F; Wang, RY; Weidner, D; Wulf, GG | 1 |
| Fujimaki, K; Fujisawa, S; Ishigatsubo, Y; Kanamori, H; Tanaka, M; Tomita, N; Yamaji, S | 1 |
| Ballard, ET; Huang, FS; Stern, LE; Warner, BW; Zwerdling, T | 1 |
8 review(s) available for daunorubicin and Cancer, Second Primary
| Article | Year |
|---|---|
Choosing induction chemotherapy in therapy-related acute myeloid leukemia.
Topics: Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Neoplasms, Second Primary | 2019 |
[Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature].
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Daunorubicin; Epstein-Barr Virus Infections; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Neoplasms, Second Primary; Risk Assessment; Treatment Outcome; Tretinoin | 2013 |
Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Synergism; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Monosomy; Neoplasms, Second Primary; Translocation, Genetic; Tretinoin | 2009 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Topics: Adenoma, Sweat Gland; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carcinoma, Acinar Cell; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Male; Mercaptopurine; Methotrexate; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Parotid Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survivors; Sweat Gland Neoplasms; Vincristine; Whole-Body Irradiation | 2008 |
Poor prognosis acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Cell Division; Cytarabine; Daunorubicin; Drug Resistance; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Neoplasms, Second Primary; Neoplastic Stem Cells; Preleukemia; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Treatment Failure | 1993 |
Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Growth Disorders; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Male; Methotrexate; Myelodysplastic Syndromes; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Survivors; Treatment Outcome; Vincristine | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
10 trial(s) available for daunorubicin and Cancer, Second Primary
| Article | Year |
|---|---|
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.
Topics: Aged; Allografts; Compassionate Use Trials; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2020 |
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quality of Life; Survival Analysis | 2021 |
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary | 2018 |
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Topics: Adolescent; Antibiotics, Antineoplastic; Bone Marrow; Child; Child, Preschool; Daunorubicin; Dose-Response Relationship, Drug; Female; Heart Diseases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Liposomes; Male; Multivariate Analysis; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2013 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Humans; Infant; Karyotyping; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 1995 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
Topics: Age Factors; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Double-Blind Method; Drug Resistance, Multiple; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recombinant Proteins | 1997 |
P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
Topics: Adult; Aged; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Cells; Cell Line; Daunorubicin; Humans; Intracellular Fluid; Leukemia, Myeloid, Acute; Leukocytes; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Prognosis; Treatment Outcome; Vault Ribonucleoprotein Particles | 1998 |
Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infections; Male; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2000 |
31 other study(ies) available for daunorubicin and Cancer, Second Primary
| Article | Year |
|---|---|
CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
Topics: Adolescent; Aged; Child; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Prospective Studies | 2022 |
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Retrospective Studies | 2022 |
Optimizing outcomes in secondary AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2022 |
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary | 2023 |
Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Topics: Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Daunorubicin; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Neoplasms, Second Primary; Postoperative Complications; Programmed Cell Death 1 Receptor; Protoporphyria, Erythropoietic; Recurrence; Remission Induction; Virus Activation; Young Adult | 2020 |
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Neoplasms, Second Primary; Treatment Outcome | 2019 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary | 2021 |
Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Daunorubicin; Drug Therapy, Combination; Fatal Outcome; Female; Humans; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Second Primary; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Soft Tissue Neoplasms; Vincristine | 2013 |
Acute myeloid leukemia of mixed megakaryocytic and erythroid origin following chemotherapy for T-cell lymphoblastic lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; Dexamethasone; Erythroid Cells; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Megakaryocytes; Mitoxantrone; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Vincristine | 2014 |
Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).
Topics: Adolescent; Adult; Aged; Anthracyclines; Anti-HIV Agents; Antibiotics, Antineoplastic; Daunorubicin; Follow-Up Studies; HIV Infections; Humans; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Risk Factors; Sarcoma, Kaposi; Treatment Outcome; Viral Load; Young Adult | 2014 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; Child; Child, Preschool; Daunorubicin; Female; Follow-Up Studies; Germany; Heterozygote; Homozygote; Humans; Infant; Leukemia, Myeloid, Acute; Male; Methyltransferases; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Vincristine | 2009 |
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Daunorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Neoplasms, Second Primary; Remission Induction; Stroke Volume | 2010 |
Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colonic Neoplasms; Colonic Polyps; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Idarubicin; Indoles; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Pyrroles; Remission Induction; Sunitinib; Time Factors; Tretinoin | 2010 |
Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Incidence; Infant; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Survival Rate; Vincristine | 2011 |
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Erythropoiesis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Middle Aged; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Pancytopenia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Vincristine | 2012 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
A thoracic-epidural granulocytic sarcoma case that was diagnosed preceding the onset of and that recurred co-incidental to acute promyelocytic leukemia, which developed after surgical treatment.
Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Epidural Space; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Sarcoma, Myeloid; Spinal Neoplasms; Thoracic Vertebrae | 2004 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma.
Topics: Adolescent; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Daunorubicin; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Orbital Neoplasms; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Vincristine | 2007 |
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Daunorubicin; Female; Humans; Infant; Male; Matched-Pair Analysis; NAD(P)H Dehydrogenase (Quinone); Neoplasms, Second Primary; Polymorphism, Genetic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Vincristine | 2007 |
[Six cases of therapy related leukemia; case reports and review of the literature].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Female; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 1993 |
[Alterations in morphological and phenotypical features of leukemic cells relapse 7 years after onset in a case of acute non-lymphocytic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Neoplasms, Second Primary; Prednisolone | 1993 |
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Mercaptopurine; Methotrexate; Methylprednisolone; Neoplasms, Second Primary; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Remission Induction; Scapula; Spinal Neoplasms; Vincristine | 1996 |
Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; DNA, Complementary; Etoposide; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Molecular Sequence Data; Muscle Proteins; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Nitrosourea Compounds; Nuclear Proteins; Oncogene Proteins, Fusion; Sequence Alignment; Sequence Homology, Nucleic Acid; src Homology Domains | 2000 |
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzimidazoles; Cell Separation; Child; Child, Preschool; Daunorubicin; Drug Resistance; Female; Humans; Immunophenotyping; Infant; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred NOD; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Transplantation; Neoplasms, Second Primary; Stem Cell Transplantation; Stem Cells; Tumor Cells, Cultured | 2001 |
Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia.
Topics: Antigens, CD7; Biomarkers, Tumor; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Mercaptopurine; Middle Aged; Neoplasms, Second Primary; Prednisolone; Trisomy | 2001 |
Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cerebral Infarction; Child; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Humans; Hypertension; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Obesity; Remission Induction; Thioguanine | 2001 |